Meredith Fisher is a Partner with Mass General Brigham Ventures where she focuses on early-stage investments and company creation. Previously, she was Director of Private Investments in the private/family office at Bracebridge Capital where she led investments in early-stage life science companies. She previously led business development for Ginkgo BioWorks, was Senior Director at PureTech Ventures, and was a scientist in anti-viral drug discovery for Idenix Pharmaceuticals and Anadys Pharmaceuticals.

Meredith currently holds board seats at BraveBio, Claris Bio, Falcon Bio, FireCyte Therapeutics, Mediar Therapeutics, Violet Therapeutics and Sena Therapeutics and serves as a board observer for Monimoi and Nocion.

Meredith holds an undergraduate degree from Mount Holyoke College, an M.B.A. from the MIT Sloan School of Management, and a PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE).